Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Equity (2022 - 2025)

Prime Medicine (PRME) has disclosed Return on Equity for 4 consecutive years, with 1.45% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 31.0% year-over-year to 1.45%, compared with a TTM value of 1.45% through Dec 2025, down 31.0%, and an annual FY2025 reading of 1.49%, down 12.0% over the prior year.
  • Return on Equity was 1.45% for Q4 2025 at Prime Medicine, up from 1.79% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.7% in Q2 2022 and bottomed at 2.61% in Q4 2022.
  • Average Return on Equity over 4 years is 1.05%, with a median of 1.14% recorded in 2024.
  • Peak annual rise in Return on Equity hit 140bps in 2023, while the deepest fall reached -149bps in 2023.
  • Year by year, Return on Equity stood at 2.61% in 2022, then surged by 54bps to 1.21% in 2023, then increased by 6bps to 1.14% in 2024, then fell by -27bps to 1.45% in 2025.
  • Business Quant data shows Return on Equity for PRME at 1.45% in Q4 2025, 1.79% in Q3 2025, and 2.38% in Q2 2025.